CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting ...

Columnist Kristin Neva says she's heard that some patients are being told they can't get feeding tubes until they have worsening problems.

Guest writer Anita Newton recounts her struggle to access help for her husband's ALS during the height of COVID-19 ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...

A noninvasive therapy delivering gentle spinal stimulation was shown to slow disease progression and extend survival in an ...

Neurizon Therapeutics has entered into a global licensing deal with Elanco Animal Health to advance the development of ...

Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.

No description.When Dagmar Munn was diagnosed with ALS at the age of 59 in 2010, she tapped into her nearly 30 years of professional health and wellness experience. She not only follows her own advice ...